 |
| Nexavar |
Building on approvals in the U.S. and EU, Bayer Healthcare said Japan has approved Nexavar to treat patients with unresectable differentiated thyroid carcinoma. Nexavar was approved in the U.S. last November for advanced thyroid cancer and by the EU in May. The drug, which Bayer shares with developer Onyx Pharmaceuticals--now part of Amgen ($AMGN)--generated €771 million ($1.06 billion) for Bayer alone in 2013. It counts certain types of kidney cancer among its FDA-approved indications. Announcement | More